SuperworthNovavax market cap NVAX
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $1.6B
- Highest close in our data
- $71.7B
- Aug 2015
Novavax is worth $1.6B at the close on Oct 23, 2026, at $9.70 a share.
That is up 16% over the last year and down 86% over five years.
Its highest close in our data was $71.7B in Aug 2015.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $1.6B | $1.2B | $2.1B | +44% |
| 2025 | $1.1B | $942.5M | $1.6B | −16% |
| 2024 | $1.3B | $466.8M | $2.6B | +133% |
| 2023 | $570.2M | $512.7M | $964.8M | −29% |
| 2022 | $807M | $758.3M | $9.6B | −93% |
| 2021 | $10.8B | $7.8B | $19.2B | +52% |
| 2020 | $7.1B | $104.4M | $9.9B | +6594% |
| 2019 | $106M | $99.3M | $17.6B | −99% |
| 2018 | $14.1B | $8.1B | $18.5B | +81% |
| 2017 | $7.8B | $4B | $9.7B | +14% |
| 2016 | $6.8B | $6.7B | $42.3B | −85% |
| 2015 | $45.3B | $27.5B | $71.7B | +60% |
| 2014 | $28.2B | $16.1B | $28.5B | +32% |
| 2013 | $21.4B | $5.3B | $21.4B | +297% |
| 2012 | $5.4B | $2.8B | $6.1B | +86% |
| 2011 | $2.9B | $2.9B | $4B | n/a |
Against its peers
Companies in Biotechnology nearest Novavax's size, closest first, today.
| Company | Market cap |
|---|---|
| NVAXNovavax | $1.6B |
| VCELVericel | $2.2B |
| ADMAAdma Biologics | $2.4B |
| MGTXMeiraGTx | $884.6M |
| KRYSKrystal Biotech | $9.2B |
| RGENRepligen | $10B |
| TECHBIO-TECHNE | $11.4B |
| PLXProtalix BioTherapeutics | $205.5M |
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| EXELExelixis | $16B |
| Peer median | $9.6B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Novavax
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.